Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer

Yi X. Chan, Matthew W. Knuiman, Mark L. Divitini, Suzanne J. Brown, John Walsh, Bu B. Yeap

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Context: Thyroid hormones modulate proliferative, metabolic and angiogenic pathways. However few studies have examined associations of thyroid hormones with cancer risk. Objectives: To explore associations of thyrotropin (TSH), free thyroxine (FT4) and anti-thyroperoxidase antibodies (TPOAb) with the incidence of all (non-skin) cancers and specific common cancers. Design and setting: A prospective cohort study of a community-dwelling population aged 25-84 years in Western Australia. Main outcome measures: Archived sera from 3649 participants in the 1994/1995 Busselton Health Survey were assayed for TSH, FT4 and TPOAb. Cancer outcomes until 30 June 2014 were ascertained using data linkage. Longitudinal analyses were performed using Cox proportional hazards regression. Results: During 20-year follow-up, 600 participants were diagnosed with non-skin cancer, including 126, 100, 103 and 41 prostate, breast, colorectal and lung cancers respectively. Higher TSH was associated with a lower risk of prostate cancer after adjusting for potential confounders, with a 30% lower risk for every 1 mIU/L increase in TSH (adjusted hazard ratio (HR): 0.70, 95% confidence interval (CI): 0.55-0.90, P = 0.005). Similarly, higher FT4 was associated with an increased risk of prostate cancer (adjusted HR: 1.11 per 1 pmol/L increase, 95% CI: 1.03-1.19, P = 0.009). There were no associations of TSH, FT4 or TPOAb with all non-skin cancer events combined, or with breast, colorectal or lung cancer. Conclusion: In a community-dwelling population, lower TSH and higher FT4 were associated with an increased risk of prostate cancer. Further studies are required to assess if thyroid function is a biomarker or risk factor for prostate cancer.

Original languageEnglish
Pages (from-to)297-308
Number of pages12
JournalEuropean Journal of Endocrinology
Volume177
Issue number4
DOIs
Publication statusPublished - 1 Oct 2017

Fingerprint

Thyroxine
Prostate
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Incidence
Independent Living
Neoplasms
Thyroid Hormones
Confidence Intervals
Western Australia
Antibodies
Information Storage and Retrieval
Thyrotropin
Metabolic Networks and Pathways
Health Surveys
Population
Anti-Idiotypic Antibodies
Thyroid Gland

Cite this

@article{cea9fb23b2c845a9988e074ca802d417,
title = "Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer",
abstract = "Context: Thyroid hormones modulate proliferative, metabolic and angiogenic pathways. However few studies have examined associations of thyroid hormones with cancer risk. Objectives: To explore associations of thyrotropin (TSH), free thyroxine (FT4) and anti-thyroperoxidase antibodies (TPOAb) with the incidence of all (non-skin) cancers and specific common cancers. Design and setting: A prospective cohort study of a community-dwelling population aged 25-84 years in Western Australia. Main outcome measures: Archived sera from 3649 participants in the 1994/1995 Busselton Health Survey were assayed for TSH, FT4 and TPOAb. Cancer outcomes until 30 June 2014 were ascertained using data linkage. Longitudinal analyses were performed using Cox proportional hazards regression. Results: During 20-year follow-up, 600 participants were diagnosed with non-skin cancer, including 126, 100, 103 and 41 prostate, breast, colorectal and lung cancers respectively. Higher TSH was associated with a lower risk of prostate cancer after adjusting for potential confounders, with a 30{\%} lower risk for every 1 mIU/L increase in TSH (adjusted hazard ratio (HR): 0.70, 95{\%} confidence interval (CI): 0.55-0.90, P = 0.005). Similarly, higher FT4 was associated with an increased risk of prostate cancer (adjusted HR: 1.11 per 1 pmol/L increase, 95{\%} CI: 1.03-1.19, P = 0.009). There were no associations of TSH, FT4 or TPOAb with all non-skin cancer events combined, or with breast, colorectal or lung cancer. Conclusion: In a community-dwelling population, lower TSH and higher FT4 were associated with an increased risk of prostate cancer. Further studies are required to assess if thyroid function is a biomarker or risk factor for prostate cancer.",
author = "Chan, {Yi X.} and Knuiman, {Matthew W.} and Divitini, {Mark L.} and Brown, {Suzanne J.} and John Walsh and Yeap, {Bu B.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1530/EJE-17-0197",
language = "English",
volume = "177",
pages = "297--308",
journal = "European Journal of Endocrinology,",
issn = "0804-4643",
publisher = "BioScientifica Ltd",
number = "4",

}

TY - JOUR

T1 - Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer

AU - Chan, Yi X.

AU - Knuiman, Matthew W.

AU - Divitini, Mark L.

AU - Brown, Suzanne J.

AU - Walsh, John

AU - Yeap, Bu B.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Context: Thyroid hormones modulate proliferative, metabolic and angiogenic pathways. However few studies have examined associations of thyroid hormones with cancer risk. Objectives: To explore associations of thyrotropin (TSH), free thyroxine (FT4) and anti-thyroperoxidase antibodies (TPOAb) with the incidence of all (non-skin) cancers and specific common cancers. Design and setting: A prospective cohort study of a community-dwelling population aged 25-84 years in Western Australia. Main outcome measures: Archived sera from 3649 participants in the 1994/1995 Busselton Health Survey were assayed for TSH, FT4 and TPOAb. Cancer outcomes until 30 June 2014 were ascertained using data linkage. Longitudinal analyses were performed using Cox proportional hazards regression. Results: During 20-year follow-up, 600 participants were diagnosed with non-skin cancer, including 126, 100, 103 and 41 prostate, breast, colorectal and lung cancers respectively. Higher TSH was associated with a lower risk of prostate cancer after adjusting for potential confounders, with a 30% lower risk for every 1 mIU/L increase in TSH (adjusted hazard ratio (HR): 0.70, 95% confidence interval (CI): 0.55-0.90, P = 0.005). Similarly, higher FT4 was associated with an increased risk of prostate cancer (adjusted HR: 1.11 per 1 pmol/L increase, 95% CI: 1.03-1.19, P = 0.009). There were no associations of TSH, FT4 or TPOAb with all non-skin cancer events combined, or with breast, colorectal or lung cancer. Conclusion: In a community-dwelling population, lower TSH and higher FT4 were associated with an increased risk of prostate cancer. Further studies are required to assess if thyroid function is a biomarker or risk factor for prostate cancer.

AB - Context: Thyroid hormones modulate proliferative, metabolic and angiogenic pathways. However few studies have examined associations of thyroid hormones with cancer risk. Objectives: To explore associations of thyrotropin (TSH), free thyroxine (FT4) and anti-thyroperoxidase antibodies (TPOAb) with the incidence of all (non-skin) cancers and specific common cancers. Design and setting: A prospective cohort study of a community-dwelling population aged 25-84 years in Western Australia. Main outcome measures: Archived sera from 3649 participants in the 1994/1995 Busselton Health Survey were assayed for TSH, FT4 and TPOAb. Cancer outcomes until 30 June 2014 were ascertained using data linkage. Longitudinal analyses were performed using Cox proportional hazards regression. Results: During 20-year follow-up, 600 participants were diagnosed with non-skin cancer, including 126, 100, 103 and 41 prostate, breast, colorectal and lung cancers respectively. Higher TSH was associated with a lower risk of prostate cancer after adjusting for potential confounders, with a 30% lower risk for every 1 mIU/L increase in TSH (adjusted hazard ratio (HR): 0.70, 95% confidence interval (CI): 0.55-0.90, P = 0.005). Similarly, higher FT4 was associated with an increased risk of prostate cancer (adjusted HR: 1.11 per 1 pmol/L increase, 95% CI: 1.03-1.19, P = 0.009). There were no associations of TSH, FT4 or TPOAb with all non-skin cancer events combined, or with breast, colorectal or lung cancer. Conclusion: In a community-dwelling population, lower TSH and higher FT4 were associated with an increased risk of prostate cancer. Further studies are required to assess if thyroid function is a biomarker or risk factor for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85029467978&partnerID=8YFLogxK

U2 - 10.1530/EJE-17-0197

DO - 10.1530/EJE-17-0197

M3 - Article

VL - 177

SP - 297

EP - 308

JO - European Journal of Endocrinology,

JF - European Journal of Endocrinology,

SN - 0804-4643

IS - 4

ER -